Table 1.
Baseline characteristics of patients with AM who received TACE+RFA or TACE alone
| Variable | TACE+RFA | TACE | χ2/t | P |
|---|---|---|---|---|
| Age, years | 54.2 ± 9.3 | 56.8 ± 8.8 | 1.108 | 0.272 |
| Gender | 0.092 | 0.762 | ||
| M | 26 (68.4%) | 18 (72.0%) | ||
| F | 12 (31.6%) | 7 (28.0%) | ||
| Child-Pugh grade | 0.076 | 0.783 | ||
| A | 30 (78.9%) | 19 (76.0%) | ||
| B | 8 (21.1%) | 6 (24.0%) | ||
| ECOG | 0.406 | 0.523 | ||
| 0 | 33 (86.8%) | 23 (92.0%) | ||
| 1 | 5 (13.2%) | 2 (8.0%) | ||
| Outcome of primary tumor | 0.834 | 0.933 | ||
| Resection | 9 (23.7%) | 5 (20.0%) | ||
| CRa | 17 (44.7%) | 12 (48.0%) | ||
| PR | 7 (18.4%) | 5 (20.0%) | ||
| SD | 1 (2.6%) | 0 | ||
| PD | 4 (10.5%) | 3 (12.0%) | ||
| Extra-adrenal metastases | 1.638 | 0.440 | ||
| None | 16 (42.1%) | 7 (28.0%) | ||
| One organ metastases | 14 (36.8%) | 13 (52.0%) | ||
| Multiple organ metastases | 8 (21.1%) | 5 (20.0%) | ||
| AM location | 0.118 | 0.731 | ||
| Unilateral | 29 (76.3%) | 20 (80.0%) | ||
| Left | 11 (28.9%) | 11 (44.0%) | ||
| Right | 18 (47.4%) | 9 (36.0%) | ||
| Bilateral | 9 (23.7%) | 5 (20.0%) | ||
| Maximal diameter of AM(cm) | 0.414 | 0.519 | ||
| ≥ 3 | 11 (23.4%) | 9 (30.0%) | ||
| <3 | 36 (76.6%) | 21 (70.0%) | ||
| Tumor size of AM(cm) | ||||
| Range | 1.5~ 7.3 | 1.2~ 8.1 | ||
| Mean | 3.3 ± 1.6 | 3.5 ± 1.7 | 0.473 | 0.637 |
Abbreviations: ECOG Eastern Cooperative Oncology Group, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, AM adrenal metastasis
Note aAssessed according to the mRECIST